For startups
Biotica Bio helps founders and R&D teams move faster with evidence, not guesswork.
What we offer
- Investor narratives — Target validation and indication rationale grounded in Open Targets data, so your story is credible and reproducible.
- Partner and BD discussions — Clear biology, disease association, and druggability summaries for out-licensing or collaboration talks.
- Pipeline prioritisation and benchmarking — Compare and benchmark drug, target, and indication potential on the same Open Targets evidence base so you can focus on the best opportunities.
- Competitive context — See how your targets sit in the landscape and where differentiation (combination, biomarker, formulation) matters most.
- Updates as data changes — Re-run the same assessment when Open Targets or other evidence updates; we can support ongoing monitoring.
The Open Targets Platform is the same evidence base that big pharma and academia use: integrated targets, diseases, drugs, and scored associations. We turn it into formats that work at your pace—credible, reproducible, and updatable.
Who this is for
- Seed to Series C biotech teams preparing for diligence.
- Scientific founders translating target biology into investor-ready positioning.
- BD and strategy teams prioritising indications and partnership narratives.
Common startup outcomes
- A clearer lead-target thesis for fundraising and partner calls.
- Evidence-backed indication prioritisation with explicit trade-offs.
- Faster responses to investor diligence questions.
Start with What we do, review an example report, then request a scoped proposal.
If useful, you can also review sector strategy notes for biotech teams and decision frameworks.